Myovant Sciences shares trading higher after agreeing to Sumitomo deal for $2.9 billion


Shares of Myovant Sciences Ltd. MYOV, +0.95% were up 8.2% in premarket trading on Monday, the day after the company said it will be acquired by Sumitomo Pharma Co. Ltd. 4506, +0.20% for $2.9 billion for the remaining shares of Myovant. Sumitomo, which already owns 52% of the company, said it will pay $27.00 per share for the remaining shares. Earlier this month, Myovant rejected Sumitomo’s acquisition attempt for $22.75 per share. The boards at both companies have agreed to the deal, which is expected to close in the first quarter of next year. Myovant’s stock is up 57.6% this year, while the broader S&P 500 SPX, +2.37% is down 21.2%.

This article was originally published by Read the original article here.

Previous articleNeed to Know: This hedge fund manager who made winning bets in 2020, says investors should brace for a decades-long bear market
Next articleGilt yields sink after former PM Boris Johnson says he won’t seek his old job


Please enter your comment!
Please enter your name here